These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 28259931)

  • 21. PTEN reconstitution alters glioma responses to c-Met pathway inhibition.
    Goodwin CR; Lal B; Ho S; Woodard CL; Zhou X; Taeger A; Xia S; Laterra J
    Anticancer Drugs; 2011 Oct; 22(9):905-12. PubMed ID: 21654317
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma.
    Kessler T; Sahm F; Blaes J; Osswald M; Rübmann P; Milford D; Urban S; Jestaedt L; Heiland S; Bendszus M; Hertenstein A; Pfenning PN; Ruiz de Almodóvar C; Wick A; Winkler F; von Deimling A; Platten M; Wick W; Weiler M
    Oncotarget; 2015 Oct; 6(31):31050-68. PubMed ID: 25682871
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Forced downregulation of RACK1 inhibits glioma development by suppressing Src/Akt signaling activity.
    Peng R; Jiang B; Ma J; Ma Z; Wan X; Liu H; Chen Z; Cheng Q; Chen R
    Oncol Rep; 2013 Nov; 30(5):2195-202. PubMed ID: 24008630
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Depletion of the triggering receptor expressed on myeloid cells 2 inhibits progression of renal cell carcinoma via regulating related protein expression and PTEN-PI3K/Akt pathway.
    Zhang H; Sheng L; Tao J; Chen R; Li Y; Sun Z; Qian W
    Int J Oncol; 2016 Dec; 49(6):2498-2506. PubMed ID: 27779645
    [TBL] [Abstract][Full Text] [Related]  

  • 25. miR-372 regulates glioma cell proliferation and invasion by directly targeting PHLPP2.
    Chen X; Hao B; Han G; Liu Y; Dai D; Li Y; Wu X; Zhou X; Yue Z; Wang L; Cao Y; Liu J
    J Cell Biochem; 2015 Feb; 116(2):225-32. PubMed ID: 25160587
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combinatorial therapy with adenoviral-mediated PTEN and a PI3K inhibitor suppresses malignant glioma cell growth in vitro and in vivo by regulating the PI3K/AKT signaling pathway.
    Nan Y; Guo L; Song Y; Wang L; Yu K; Huang Q; Zhong Y
    J Cancer Res Clin Oncol; 2017 Aug; 143(8):1477-1487. PubMed ID: 28401302
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MCL1 gene silencing promotes senescence and apoptosis of glioma cells via inhibition of the PI3K/Akt signaling pathway.
    Wu DM; Hong XW; Wen X; Han XR; Wang S; Wang YJ; Shen M; Fan SH; Zhuang J; Zhang ZF; Shan Q; Li MQ; Hu B; Sun CH; Lu J; Zheng YL
    IUBMB Life; 2019 Jan; 71(1):81-92. PubMed ID: 30296359
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Investigation of the anti-glioma activity of Oviductus ranae protein hydrolysate.
    Sui X; Li XH; Duan MH; Jia AL; Wang Y; Liu D; Li YP; Qiu ZD
    Biomed Pharmacother; 2016 Jul; 81():176-181. PubMed ID: 27261592
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MicroRNA-379 inhibits cell proliferation and invasion in glioma via targeting metadherin and regulating PTEN/AKT pathway.
    Li L; Zhang H
    Mol Med Rep; 2018 Mar; 17(3):4049-4056. PubMed ID: 29286115
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MicroRNA miR-451 downregulates the PI3K/AKT pathway through CAB39 in human glioma.
    Tian Y; Nan Y; Han L; Zhang A; Wang G; Jia Z; Hao J; Pu P; Zhong Y; Kang C
    Int J Oncol; 2012 Apr; 40(4):1105-12. PubMed ID: 22179124
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-Tumor Effects of Sodium Meta-Arsenite in Glioblastoma Cells with Higher Akt Activities.
    Lee EJ; Sung JY; Koo KH; Park JB; Kim DH; Shim J; Lee CH; Park J; Kim YN
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33256086
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MicroRNA‑93‑5p promotes the progression of human retinoblastoma by regulating the PTEN/PI3K/AKT signaling pathway.
    Cao Y; Xia F; Wang P; Gao M
    Mol Med Rep; 2018 Dec; 18(6):5807-5814. PubMed ID: 30365088
    [TBL] [Abstract][Full Text] [Related]  

  • 33. AQP8 promotes glioma proliferation and growth, possibly through the ROS/PTEN/AKT signaling pathway.
    Hao Z; Huajun S; Zhen G; Yu X; Qian L; Ziling C; Zihao S; Qingqian X; Shujuan Z
    BMC Cancer; 2023 Jun; 23(1):516. PubMed ID: 37280594
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PTEN down regulates AP-1 and targets c-fos in human glioma cells via PI3-kinase/Akt pathway.
    Koul D; Shen R; Shishodia S; Takada Y; Bhat KP; Reddy SA; Aggarwal BB; Yung WK
    Mol Cell Biochem; 2007 Jun; 300(1-2):77-87. PubMed ID: 17235455
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Effects of FPR2 gene silencing on the proliferation, migration and invasion of human glioma U87 cells].
    Liu L; Li X; Shi J; Li L; Wang J; Luo ZZ
    Zhonghua Zhong Liu Za Zhi; 2018 Sep; 40(9):659-666. PubMed ID: 30293389
    [No Abstract]   [Full Text] [Related]  

  • 36. Knockdown of PREX2a inhibits the malignant phenotype of glioma cells.
    Liu L; Liu Z; Wang H; Chen L; Ruan F; Zhang J; Hu Y; Luo H; Wen S
    Mol Med Rep; 2016 Mar; 13(3):2301-7. PubMed ID: 26795161
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The antipsychotic agent chlorpromazine induces autophagic cell death by inhibiting the Akt/mTOR pathway in human U-87MG glioma cells.
    Shin SY; Lee KS; Choi YK; Lim HJ; Lee HG; Lim Y; Lee YH
    Carcinogenesis; 2013 Sep; 34(9):2080-9. PubMed ID: 23689352
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Inhibitory effect of knocking down microRNA-221 and microRNA-222 on glioma cell growth in vitro and in vivo].
    Zhang CZ; Kang CS; Pu PY; Wang GX; Jia ZF; Zhang AL; Han L; Xu P
    Zhonghua Zhong Liu Za Zhi; 2009 Oct; 31(10):721-6. PubMed ID: 20021821
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The PTEN/Akt pathway dictates the direct alphaVbeta3-dependent growth-inhibitory action of an active fragment of tumstatin in glioma cells in vitro and in vivo.
    Kawaguchi T; Yamashita Y; Kanamori M; Endersby R; Bankiewicz KS; Baker SJ; Bergers G; Pieper RO
    Cancer Res; 2006 Dec; 66(23):11331-40. PubMed ID: 17145879
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.
    Koul D; Wang S; Wu S; Saito N; Zheng S; Gao F; Kaul I; Setoguchi M; Nakayama K; Koyama K; Shiose Y; Sulman EP; Hirota Y; Yung WKA
    Oncotarget; 2017 Mar; 8(13):21741-21753. PubMed ID: 28423515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.